Mackenzie Financial Buys More Shares of Castle Biosciences

Summary

Mackenzie Financial Corporation acquired 21,020 shares of Castle Biosciences, Inc. (NASDAQ:CSTL) during the fourth quarter of 2023, amounting to approximately $560,000. Other institutional investors also increased their positions in CSTL. The stock is currently trading at $16.27, with a market capitalization of $469.75 million. Castle Biosciences reported last quarter revenues of $87.99 million, failing to meet earnings per share expectations. Analysts have a consensus rating of ‘Buy’ for CSTL, with an average target price of $37.00.Market Beat

Impact Analysis

The event is classified at the company level, as it pertains to specific investment actions involving Castle Biosciences by Mackenzie Financial Corporation. The increase in institutional holdings suggests confidence in Castle Biosciences’ future prospects despite recent earnings not meeting expectations. This could lead to positive sentiment among investors and potentially drive the stock price towards the analyst target price of $37.00.Market Beat Additionally, the current trading price of $16.27 provides a significant upside opportunity if the average target price is considered. However, investors should be cautious of potential volatility due to past earnings misses, which might influence short-term market reactions. The ‘Buy’ consensus rating among analysts indicates a favorable long-term outlook, aligning with Mackenzie’s decision to increase its holdings.Market Beat